TCL Archive Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money December 2, 1983
TCL Archive In Brief: Override Failure Would Leave Cancer Program With No Money or New Projects Of Any Kind January 23, 1976
TCL Archive FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says. January 14, 2005
